

**APPLICANT** (stamp or sticker acceptable) **PATIENT NHI:** ..... **REFERRER** Reg No: .....

Reg No: ..... First Names: ..... First Names: .....

Name: ..... Surname: ..... Surname: .....

Address: ..... DOB: ..... Address: .....

..... Address: ..... .....

..... .....

Fax Number: ..... Fax Number: .....

## Enoxaparin sodium

### Initial application — Pregnancy, Malignancy or Haemodialysis

Applications from any relevant practitioner. Approvals valid for 1 year.

**Prerequisites**(tick boxes where appropriate)

- ☐ Low molecular weight heparin treatment is required during a patients pregnancy  
or  
☐ For the treatment of venous thromboembolism where the patient has a malignancy  
or  
☐ For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis

### Initial application — Venous thromboembolism other than in pregnancy or malignancy

Applications from any relevant practitioner. Approvals valid for 1 month.

**Prerequisites**(tick boxes where appropriate)

- ☐ For the short-term treatment of venous thromboembolism prior to establishing a therapeutic level of oral anti-coagulant treatment  
or  
☐ For the prophylaxis and treatment of venous thromboembolism in high risk surgery  
or  
☐ To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery  
or  
☐ For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention  
or  
☐ To be used in association with cardioversion of atrial fibrillation

### Initial application — Short-term use during treatment of COVID-19 with nirmatrelvir with ritonavir

Applications from any relevant practitioner. Approvals valid for 2 weeks.

**Prerequisites**(tick boxes where appropriate)

- ☐ Patient is receiving an anticoagulation treatment that has drug/drug interactions with ritonavir that increases risk of bleeding  
and  
☐ Patient meets the Access Criteria for COVID-19 antivirals published on the Pharmac website\*  
and  
☐ Other antiviral treatments for COVID-19 have been considered and are not clinically suitable options

### Renewal — Pregnancy, Malignancy or Haemodialysis

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 1 year.

**Prerequisites**(tick boxes where appropriate)

- ☐ Low molecular weight heparin treatment is required during a patient's pregnancy  
or  
☐ For the treatment of venous thromboembolism where the patient has a malignancy  
or  
☐ For the prevention of thrombus formation in the extra-corporeal circulation during haemodialysis

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ..... Date: .....

Post application to Ministry of Health, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT</b> NHI: .....	<b>REFERRER</b> Reg No: .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	Address: .....	.....
.....	.....	.....
Fax Number: .....	.....	Fax Number: .....

**Enoxaparin sodium** - continued

**Renewal — Venous thromboembolism other than in pregnancy or malignancy**

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 1 month.

**Prerequisites**(tick box where appropriate)

- ☐ Low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation)

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ..... Date: .....

Post application to Ministry of Health, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)